Tiffany Kirk
Family · Marshfield, MONPI 1619491024
Payments from drug & device makers
Across 190 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$741
- AbbVie$695
- Neurocrine Biosciences, Inc.$431
- Otsuka America Pharmaceutical, Inc.$399
- GSK$263
- Axsome Therapeutics, Inc.$218
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,884100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $741 |
| AbbVie | 43 | $695 |
| Neurocrine Biosciences, Inc. | 16 | $431 |
| Otsuka America Pharmaceutical, Inc. | 14 | $399 |
| GSK | 14 | $263 |
| Axsome Therapeutics, Inc. | 4 | $218 |
| Teva Pharmaceuticals USA, Inc. | 12 | $205 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $174 |
| Pfizer | 6 | $102 |
| Vifor Pharma, Inc. | 1 | $95 |
| Boehringer Ingelheim | 5 | $79 |
| Radius Health, Inc. | 3 | $70 |
| Lilly USA, LLC | 4 | $61 |
| Mylan Specialty L.p. | 3 | $44 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Astellas Pharma US Inc | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Viatris Specialty LLC | 1 | $25 |
| Braeburn Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Novartis | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$126
- REXULTI$122
- INGREZZA$103
- TRELEGY ELLIPTA$103
- UBRELVY$101
How this compares
$3,899 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 69 | $386,781 |
| IngrezzaValbenazine Tosylate | 25 | $215,300 |
| FarxigaDapagliflozin Propanediol | 114 | $76,154 |
| Nurtec OdtRimegepant Sulfate | 49 | $70,269 |
| Fasenra PenBenralizumab | 12 | $68,991 |
| TrulicityDulaglutide | 44 | $61,813 |
| OzempicSemaglutide | 55 | $54,682 |
| VraylarCariprazine Hcl | 31 | $47,883 |
| UbrelvyUbrogepant | 36 | $45,889 |
| Budesonide ErBudesonide | 14 | $27,044 |
| EliquisApixaban | 43 | $25,556 |
| Emgality PenGalcanezumab-Gnlm | 26 | $23,051 |
| LinzessLinaclotide | 35 | $19,677 |
| TrintellixVortioxetine Hydrobromide | 36 | $19,643 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $19,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $205 | $386,78169 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $431 | $215,30025 claims |
| AbbVieVraylar, Ubrelvy, Linzess | $695 | $113,448102 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $741 | $100,024160 claims |
| PfizerNurtec Odt, Eliquis | $102 | $95,82592 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $61 | $79,27558 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $31 | $19,64336 claims |
| Boehringer IngelheimJardiance | $79 | $18,36624 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $174 | $17,98611 claims |
| GSKBreo Ellipta | $263 | $10,92322 claims |
| NovartisEntresto | $12 | $7,81513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Marshfield
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.